1
|
Soto M, Andrieu S, Gares V, Cesari M, Gillette-Guyonnet S, Cantet C, Vellas B, Nourhashémi F. Living Alone with Alzheimer's Disease and the Risk of Adverse Outcomes: Results from the Plan de Soin et d'Aide dans la maladie d'Alzheimer Study. J Am Geriatr Soc 2015; 63:651-8. [PMID: 25900483 DOI: 10.1111/jgs.13347] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
Abstract
OBJECTIVES To examine whether living alone predicted hospitalizations, nursing home admission, weight loss, and death in individuals with mild to moderate Alzheimer's disease (AD) over 2 years of follow-up. DESIGN Data are from the Plan de Soin et d'Aide dans la maladie d'Alzheimer study, a 24-month trial with a cluster randomization of memory clinics in two arms: a multidomain intervention and usual care. SETTING Memory clinics in France (N = 50). PARTICIPANTS Community-dwelling individuals with AD with a Mini-Mental State Examination score between 12 and 26 and an identified caregiver. MEASUREMENTS A neurogeriatric evaluation was conducted twice a year in the intervention group and annually in the control group. Hospitalizations, nursing home admission, weight loss, and death occurring during the past year were recorded. Information on sociodemographic characteristics, clinical conditions, therapy, and physical and cognitive status was recorded. RESULTS At inclusion, 348 (30.8%) of the 1,131 participants lived alone. Living alone did not increase the risk of mortality or weight loss in individuals with mild to moderate AD, but significant associations with risk of hospitalization (hazard ratio (HR) = 1.33, 95% confidence interval (CI) = 1.01-1.74) and institutionalization (HR = 2.53, 95% CI = 1.84-3.47) were reported. A protective effect of physical function on institutionalization and mortality was found. CONCLUSION These results might support clinicians in making decisions about institutionalization of individuals with AD living alone or improving home health care, such as increasing screening and managing functional impairment in this complex population.
Collapse
Affiliation(s)
- Maria Soto
- Department of Geriatric Medicine, Gérontopôle, Centre Hospitalier Universitaire ToulouseToulouse University Hospital, Toulouse, France; Inserm UMR 1027, Toulouse, France; Université Toulouse III, Toulouse, France
| | | | | | | | | | | | | | | |
Collapse
|
2
|
de Mauleon A, Sourdet S, Renom-Guiteras A, Gillette-Guyonnet S, Leino-Kilpi H, Karlsson S, Bleijlevens M, Zabategui A, Saks K, Vellas B, Jolley D, Soto M. Associated factors with antipsychotic use in long-term institutional care in eight European countries: Results from the RightTimePlaceCare study. J Am Med Dir Assoc 2014; 15:812-8. [PMID: 25129474 DOI: 10.1016/j.jamda.2014.06.015] [Citation(s) in RCA: 29] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/03/2014] [Revised: 06/15/2014] [Accepted: 06/19/2014] [Indexed: 11/29/2022]
Abstract
OBJECTIVES To determine factors associated with the antipsychotic (AP) prescription for people with dementia (PwD) recently admitted to institutional long-term care facilities (LTCFs) and to ascertain differences in the use of this medication in 8 European countries. DESIGN An exploratory cross-sectional study. SETTING LTCFs from 8 European countries (Estonia, Finland, France, Germany, The Netherlands, Spain, Sweden, and England). PARTICIPANTS A total of 791 PwD recently admitted to an LTCF and their caregivers. MEASUREMENTS Baseline data from RightTimePlaceCare survey was used. Patients' medical conditions, neuropsychiatric symptoms, physical and cognitive status, and medications were recorded. Multiple logistic regression models were used to assess associations with the AP use. RESULTS A group of 296 patients (37.4%) of 791 patients recently admitted received AP medication. The prevalence of the use of 1 or more APs varied between study countries, ranging from 12% in Sweden to 54% in Spain. Factors independently associated with the AP use were living in Sweden [odds ratio (OR) 0.12, 95% confidence interval (CI) 0.05-0.30], Finland (OR 0.26, 95% CI 0.14-0.48), Germany (OR 2.75, 95% CI 1.55-4.86) and Estonia (OR 6.79, 95% CI 3.84-12.0). The odds of AP use decreased with the presence of a dementia specific unit in the LTCF (OR 0.60, 95% CI 0.39-0.92), but was higher among residents with a hyperactivity behavior (OR 2.12, 95% CI 1.41-3.18). CONCLUSION The current study shows that more than one-third of the residents recently admitted received APs and that prescription frequency across countries varied significantly. This study raises the possibility that the presence of a dementia-specific unit might play a role in the AP use. Further studies should investigate this association and seek better understanding of what will achieve optimal quality of AP use among newly admitted residents in LTCF.
Collapse
Affiliation(s)
- Adelaide de Mauleon
- Department of Geriatric Medicine, Gerontopole, Toulouse University Hospital, INSERM 1027, Toulouse, France
| | - Sandrine Sourdet
- Department of Geriatric Medicine, Gerontopole, Toulouse University Hospital, INSERM 1027, Toulouse, France
| | - Anna Renom-Guiteras
- Institut fuer Allgemeinmedizin und Familienmedizin, Universitaet Witten/Herdecke, Witten, Germany
| | - Sophie Gillette-Guyonnet
- Department of Geriatric Medicine, Gerontopole, Toulouse University Hospital, INSERM 1027, Toulouse, France
| | | | | | - Michel Bleijlevens
- Department of Health Services Research, Maastricht University, Maastricht, The Netherlands
| | | | - Kai Saks
- Department of Internal Medicine, University of Tartu, Tartu, Estonia
| | - Bruno Vellas
- Department of Geriatric Medicine, Gerontopole, Toulouse University Hospital, INSERM 1027, Toulouse, France
| | - David Jolley
- Personal Social Services Research Unit, University of Manchester, Manchester, UK
| | - Maria Soto
- Department of Geriatric Medicine, Gerontopole, Toulouse University Hospital, INSERM 1027, Toulouse, France.
| | | |
Collapse
|
3
|
Vellas B, Carrie I, Gillette-Guyonnet S, Touchon J, Dantoine T, Dartigues JF, Cuffi MN, Bordes S, Gasnier Y, Robert P, Bories L, Rouaud O, Desclaux F, Sudres K, Bonnefoy M, Pesce A, Dufouil C, Lehericy S, Chupin M, Mangin JF, Payoux P, Adel D, Legrand P, Catheline D, Kanony C, Zaim M, Molinier L, Costa N, Delrieu J, Voisin T, Faisant C, Lala F, Nourhashémi F, Rolland Y, Van Kan GA, Dupuy C, Cantet C, Cestac P, Belleville S, Willis S, Cesari M, Weiner MW, Soto ME, Ousset PJ, Andrieu S. MAPT STUDY: A MULTIDOMAIN APPROACH FOR PREVENTING ALZHEIMER'S DISEASE: DESIGN AND BASELINE DATA. J Prev Alzheimers Dis 2014; 1:13-22. [PMID: 26594639 PMCID: PMC4652787] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/05/2023]
Abstract
OBJECTIVE The Multidomain Alzheimer Preventive Trial (MAPT study) was designed to assess the efficacy of isolated supplementation with omega-3 fatty acid, an isolated multidomain intervention (consisting of nutritional counseling, physical exercise, cognitive stimulation) or a combination of the two interventions on the change of cognitive functions in frail subjects aged 70 years and older for a period of 3 years. Ancillary neuroimaging studies were additionally implemented to evaluate the impact of interventions on cerebral metabolism (FDG PET scans) and atrophy rate (MRIs), as well as brain amyloïd deposit (AV45 PET scans). DESIGN PATIENTS 1680 subjects (mean age: 75.3 years; female: 64.8 %), enrolled by 13 memory clinics, were randomized into one of the following four groups: omega-3 supplementation alone, multidomain intervention alone, omega-3 plus multidomain intervention, or placebo. Participants underwent cognitive, functional and biological assessments at M6, M12, M24 and M36 visits. The primary endpoint is a change of memory function at 3 years, as assessed by the Free and Cued Selective Reminding test. All participants will be followed for 2 additional years after the 3-years intervention (MAPT PLUS extension study). INTERVENTIONS 1/Omega-3 supplementation: two soft capsules daily as a single dose, containing a total of 400 mg docosahexaenoic acid (DHA), i.e., 800 mg docosahexaenoic acid per day, for 3 years. 2/ Multidomain intervention: collective training sessions conducted in small groups (6-8 participants) in twelve 120-minute sessions over the first 2 months (two sessions a week for the first month, and one session a week the second month) then a 60-minute session per month in the following three areas: nutrition, physical activity, and cognition until the end of the 3 years. In addition to the collective sessions, individualized preventive outpatient visits exploring possible risk factors for cognitive decline are performed at baseline, M12 and M24. BASELINE POPULATION For cognition, the mean MMSE at baseline was 28.1 (± 1.6). About 58% and 42% of participants had a CDR score equal to 0 and 0.5, respectively. Regarding mobility status, 200 (11.9%) had a 4-m gait speed lower or equal to 0.8 m/s. According to the Fried criteria, 673 (42.1%) participants were considered pre frail, and 51 (3.2%) frail. The red blood cell DHA content was 26.1 ± 8.1 µg/g. Five hundred and three participants underwent baseline MRI. AV45 PET scans were performed in 271 individuals and preliminary results showed that 38.0% had a cortical SUVR > 1.17, which gave an indication of significant brain amyloïd deposit. DISCUSSION: The MAPT trial is presently the first largest and longest multidomain preventive trial relevant to cognitive decline in older adults with subjective memory complaints. The multidomain intervention designed for the MAPT trial is likely to be easily implemented within the general population.
Collapse
Affiliation(s)
- B Vellas
- Gérontopôle, Department of Geriatrics, CHU Toulouse, Purpan University Hospital, Toulouse, France ; INSERM UMR 1027, Toulouse, France ; University of Toulouse III, Toulouse, France
| | - I Carrie
- Gérontopôle, Department of Geriatrics, CHU Toulouse, Purpan University Hospital, Toulouse, France
| | - S Gillette-Guyonnet
- Gérontopôle, Department of Geriatrics, CHU Toulouse, Purpan University Hospital, Toulouse, France ; INSERM UMR 1027, Toulouse, France ; University of Toulouse III, Toulouse, France
| | - J Touchon
- Department of Neurology, Memory Research Resource Center for Alzheimer's Disease, University Hospital of Montpellier, Montpellier, France
| | - T Dantoine
- Geriatrics Department, Memory Research Resource Center, University Hospital of Limoges, Limoges, France
| | - J F Dartigues
- INSERM U897, Memory Research Resource Center for Alzheimer's Disease, University Hospital of Bordeaux, Bordeaux, France
| | - M N Cuffi
- Geriatrics Department, Hospital of Castres, Castres, France
| | - S Bordes
- Geriatrics Department, Hospital of Tarbes, Tarbes, France
| | - Y Gasnier
- Geriatrics Department, Hospital of Tarbes, Tarbes, France
| | - P Robert
- Memory Research Resource Center, University Hospital of Nice, Nice, France
| | - L Bories
- Geriatrics Department, Hospital of Foix, Foix, France
| | - O Rouaud
- Memory Research Resource Center, Neurology Department, University Hospital of Dijon, Dijon, France
| | - F Desclaux
- Geriatrics Department, Hospital of Lavaur, Lavaur, France
| | - K Sudres
- Geriatrics Department, Hospital of Montauban, Montauban, France
| | - M Bonnefoy
- Geriatrics Department, Centre Hospitalier Lyon-Sud, Lyon, France
| | - A Pesce
- Geriatrics Department, Hospital of Princess Grace, Monaco
| | - C Dufouil
- INSERM Center U897, CIC-EC7, Bordeaux University, Department of Public Health of CHU Bordeaux, Bordeaux, France
| | - S Lehericy
- Neuroradiology Department, Pitié-Salpêtrière Hospital, Paris, France
| | - M Chupin
- Neuroradiology Department, Pitié-Salpêtrière Hospital, Paris, France
| | - J F Mangin
- CATI, NeuroSpin, CEA-Saclay Center, Gif-sur-Yvette, France
| | - P Payoux
- INSERM UMR 825, Toulouse, France ; Department of Nuclear Medicine, CHU Toulouse, Purpan University Hospital, Toulouse, France
| | - D Adel
- INSERM UMR 825, Toulouse, France
| | - P Legrand
- Nutrition Department, Agrocampus-INRA, Rennes, France
| | - D Catheline
- Nutrition Department, Agrocampus-INRA, Rennes, France
| | - C Kanony
- Institut de Recherche Pierre Fabre, Toulouse, France
| | - M Zaim
- Institut de Recherche Pierre Fabre, Toulouse, France
| | - L Molinier
- INSERM UMR 1027, Toulouse, France ; University of Toulouse III, Toulouse, France ; Department of Medical Information, CHU Toulouse, Toulouse, France
| | - N Costa
- INSERM UMR 1027, Toulouse, France ; University of Toulouse III, Toulouse, France ; Department of Medical Information, CHU Toulouse, Toulouse, France
| | - J Delrieu
- Gérontopôle, Department of Geriatrics, CHU Toulouse, Purpan University Hospital, Toulouse, France
| | - T Voisin
- Gérontopôle, Department of Geriatrics, CHU Toulouse, Purpan University Hospital, Toulouse, France ; INSERM UMR 1027, Toulouse, France ; University of Toulouse III, Toulouse, France
| | - C Faisant
- Gérontopôle, Department of Geriatrics, CHU Toulouse, Purpan University Hospital, Toulouse, France
| | - F Lala
- Gérontopôle, Department of Geriatrics, CHU Toulouse, Purpan University Hospital, Toulouse, France
| | - F Nourhashémi
- Gérontopôle, Department of Geriatrics, CHU Toulouse, Purpan University Hospital, Toulouse, France ; INSERM UMR 1027, Toulouse, France ; University of Toulouse III, Toulouse, France
| | - Y Rolland
- Gérontopôle, Department of Geriatrics, CHU Toulouse, Purpan University Hospital, Toulouse, France ; INSERM UMR 1027, Toulouse, France ; University of Toulouse III, Toulouse, France
| | - G Abellan Van Kan
- Gérontopôle, Department of Geriatrics, CHU Toulouse, Purpan University Hospital, Toulouse, France ; INSERM UMR 1027, Toulouse, France ; University of Toulouse III, Toulouse, France
| | - C Dupuy
- Gérontopôle, Department of Geriatrics, CHU Toulouse, Purpan University Hospital, Toulouse, France ; INSERM UMR 1027, Toulouse, France
| | - C Cantet
- Gérontopôle, Department of Geriatrics, CHU Toulouse, Purpan University Hospital, Toulouse, France ; INSERM UMR 1027, Toulouse, France ; University of Toulouse III, Toulouse, France
| | - P Cestac
- Gérontopôle, Department of Geriatrics, CHU Toulouse, Purpan University Hospital, Toulouse, France ; INSERM UMR 1027, Toulouse, France ; University of Toulouse III, Toulouse, France
| | - S Belleville
- Research Center, Institut Universitaire de Gériatrie de Montréal, Montréal, Canada
| | - S Willis
- Department of Psychiatry and Behavioral Sciences, University of Washington, Washington, USA
| | - M Cesari
- Gérontopôle, Department of Geriatrics, CHU Toulouse, Purpan University Hospital, Toulouse, France ; INSERM UMR 1027, Toulouse, France ; University of Toulouse III, Toulouse, France
| | - M W Weiner
- University of California, San Francisco, California, United States
| | - M E Soto
- Gérontopôle, Department of Geriatrics, CHU Toulouse, Purpan University Hospital, Toulouse, France ; INSERM UMR 1027, Toulouse, France ; University of Toulouse III, Toulouse, France
| | - P J Ousset
- Gérontopôle, Department of Geriatrics, CHU Toulouse, Purpan University Hospital, Toulouse, France ; INSERM UMR 1027, Toulouse, France ; University of Toulouse III, Toulouse, France
| | - S Andrieu
- Gérontopôle, Department of Geriatrics, CHU Toulouse, Purpan University Hospital, Toulouse, France ; INSERM UMR 1027, Toulouse, France ; University of Toulouse III, Toulouse, France ; Department of Epidemiology and Public Health, CHU Toulouse, Toulouse, France
| |
Collapse
|
4
|
Vellas B, Gillette-Guyonnet S, Touchon J, Dantoine T, Dartigues J, Cuffi M, Bordes S, Gasnier Y, Robert P, Bories L, Rouaud O, Desclaux F, Sudres K, Bonnefoy M, Pesce A, Dufouil C, Lehericy S, Chupin M, Mangin J, Payoux P, Adel D, Legrand P, Catheline D, Kanony C, Zaim M, Molinier L, Costa N, Delrieu J, Voisin T, Faisant C, Lala F, Nourhashemi F, Rolland Y, Abellan Van Kan G, Dupuy C, Cantet C, Cestac P, Belleville S, Willis S, Cesari M, Weiner M, Soto M, Ousset P, Andrieu S, Carrie I. MAPT STUDY: A MULTIDOMAIN APPROACH FOR PREVENTING ALZHEIMER’S DISEASE: DESIGN AND BASELINE DATA. J Prev Alzheimers Dis 2014. [DOI: 10.14283/jpad.2014.34] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Abstract
Objective: The Multidomain Alzheimer Preventive Trial (MAPT study) was designed to assess the efficacy of isolated supplementation with omega-3 fatty acid, an isolated multidomain intervention (consisting of nutritional counseling, physical exercise, cognitive stimulation) or a combination of the two interventions on the change of cognitive functions in frail subjects aged 70 years and older for a period of 3 years. Ancillary neuroimaging studies were additionally implemented to evaluate the impact of interventions on cerebral metabolism (FDG PET scans) and atrophy rate (MRIs), as well as brain amyloïd deposit (AV45 PET scans). Design, patients: 1680 subjects (mean age: 75.3 years; female: 64.8 %), enrolled by 13 memory clinics, were randomized into one of the following four groups: omega-3 supplementation alone, multidomain intervention alone, omega-3 plus multidomain intervention, or placebo. Participants underwent cognitive, functional and biological assessments at M6, M12, M24 and M36 visits. The primary endpoint is a change of memory function at 3 years, as assessed by the Free and Cued Selective Reminding test. All participants will be followed for 2 additional years after the 3-years intervention (MAPT PLUS extension study). Interventions: 1/ Omega-3 supplementation: two soft capsules daily as a single dose, containing a total of 400 mg docosahexaenoic acid (DHA), i.e., 800 mg docosahexaenoic acid per day, for 3 years. 2/ Multidomain intervention: collective training sessions conducted in small groups (6–8 participants) in twelve 120-minute sessions over the first 2 months (two sessions a week for the first month, and one session a week the second month) then a 60-minute session per month in the following three areas: nutrition, physical activity, and cognition until the end of the 3 years. In addition to the collective sessions, individualized preventive outpatient visits exploring possible risk factors for cognitive decline are performed at baseline, M12 and M24. Baseline population: For cognition, the mean MMSE at baseline was 28.1 (± 1.6). About 58% and 42% of participants had a CDR score equal to 0 and 0.5, respectively. Regarding mobility status, 200 (11.9%) had a 4-m gait speed lower or equal to 0.8 m/s. According to the Fried criteria, 673 (42.1%) participants were considered pre frail, and 51 (3.2%) frail. The red blood cell DHA content was 26.1 ± 8.1 µg/g. Five hundred and three participants underwent baseline MRI. AV45 PET scans were performed in 271 individuals and preliminary results showed that 38.0% had a cortical SUVR > 1.17, which gave an indication of significant brain amyloïd deposit. Discussion: The MAPT trial is presently the first largest and longest multidomain preventive trial relevant to cognitive decline in older adults with subjective memory complaints. The multidomain intervention designed for the MAPT trial is likely to be easily implemented within the general population.
Collapse
|
5
|
Secher M, Andrieu S, Gillette-Guyonnet S, Soto M, Rolland Y, Cantet C, Vellas B, Ritz P. Weight changes in Alzheimer's disease patients with increased aberrant motor behavior. Int J Geriatr Psychiatry 2013. [PMID: 23208785 DOI: 10.1002/gps.3914] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/07/2022]
Abstract
OBJECTIVE Weight loss and behavioral disturbances are frequent over the course of Alzheimer's disease (AD) and are risk factors for poor outcome. We investigated the impact of aberrant motor behavior (AMB) on weight changes in older adults with AD. The hypothesis that patients with AMB are more likely to lose weight than patients without AMB was assessed. METHODS A prospective study of 686 patients with moderate AD from the REAL.FR cohort was assessed. The AMB at baseline was defined by the item 10 from the Neuropsychiatric Inventory scale (NPI-10). Patients were classified as "no or light AMB" (NPI-10 < 4), and "significant AMB" (NPI-10 ≥ 4). Weight changes were determined over the 4-year follow-up. RESULTS The mean weight change over the 4 years was +2.2 ± 0.9 kg in patients with "significant AMB," whereas weight remained stable in patients with "no or light AMB" (p = 0.02). CONCLUSION Older adults with moderate AD and "significant AMB" do gain weight.
Collapse
Affiliation(s)
- Marion Secher
- University of Toulouse III, F-31073, Toulouse, France; Gerontopole, CMRR, F-31059, Toulouse, France
| | | | | | | | | | | | | | | | | |
Collapse
|
6
|
Soto ME, van Kan GA, Nourhashemi F, Gillette-Guyonnet S, Cesari M, Cantet C, Rolland Y, Vellas B. Angiotensin-converting enzyme inhibitors and Alzheimer's disease progression in older adults: results from the Réseau sur la Maladie d'Alzheimer Français cohort. J Am Geriatr Soc 2013; 61:1482-8. [PMID: 24000874 DOI: 10.1111/jgs.12415] [Citation(s) in RCA: 48] [Impact Index Per Article: 4.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Abstract
OBJECTIVES To assess whether angiotensin-converting enzyme inhibitor (ACE-I) treatment is associated with less cognitive decline in older adults with Alzheimer's disease (AD) than in those using other hypertensive or no drugs. DESIGN Four-year prospective multicenter cohort study with a biannual assessment. SETTING Memory clinics from 16 university hospitals in France. PARTICIPANTS Community-dwelling older adults with mild to moderate AD (N = 616). MEASUREMENTS Participants were stratified into four groups according to type and duration of antihypertensive drug treatment. Cognitive decline was assessed using the Mini-Mental State Examination (MMSE). Linear mixed-effects models were used to assess differences in decline in MMSE score between the four groups. Hypertension at each visit was included in the model. RESULTS Sixty-one participants had used ACE-Is continuously, 57 had used them intermittently, 189 had used other antihypertensive drugs, and 309 never used any antihypertensive drugs. Continuous ACE-Is users had a 4-year decline in MMSE of 6.4 ± 1.6 points (P < .001), intermittent ACE-Is users of 7.9 ± 1.1 points (P < .001), continuous or intermittent users of other antihypertensive drugs of 8.8 ± 0.7 points (P < .001), and never-users of 10.2 ± 0.6 points (P < .001). MMSE decline between the four groups was significantly different (adjusted P = .02). In subgroup analysis, the 118 (19.2%) participants who had continuously or intermittently used ACE-Is had a significant difference in 4-year MMSE decline from the 498 (80.8%) who had never used ACE-Is (7.5 ± 0.9 vs 9.7 ± 0.4; P = .03). CONCLUSION The use of ACE-Is in older adults with AD is associated with a slower rate of cognitive decline independent of hypertension. Future research is needed to explore the role of ACE-Is in long-term AD progression.
Collapse
Affiliation(s)
- Maria E Soto
- Department of Geriatric Medicine, Gérontopôle, CHU Toulouse University Hospital, Toulouse, France; Inserm, UMR1027, Toulouse, France
| | | | | | | | | | | | | | | |
Collapse
|
7
|
van Kan GA, Cesari M, Gillette-Guyonnet S, Dupuy C, Vellas B, Rolland Y. Association of a 7-year percent change in fat mass and muscle mass with subsequent cognitive dysfunction: the EPIDOS-Toulouse cohort. J Cachexia Sarcopenia Muscle 2013; 4:225-9. [PMID: 23888380 PMCID: PMC3774918 DOI: 10.1007/s13539-013-0112-z] [Citation(s) in RCA: 21] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/27/2012] [Accepted: 06/23/2013] [Indexed: 11/06/2022] Open
Abstract
BACKGROUND Cognitive dysfunction and changes in body composition share common pathophysiological pathways. The aim of the present paper was to evaluate whether changes in appendicular muscle mass (AMM) and fat mass (FM) are associated factors with an increased risk of cognitive dysfunction in community-dwelling older women. METHODS A nested case-control study was performed in 181 women aged 75 years and older from a subsample of the Epidemiologie de l'Osteoporose participants from Toulouse. Body composition parameters at inclusion and 7 years later (assessed by dual energy X-ray absorptiometry), and the presence of cognitive dysfunction (dementia and mild cognitive impairment) at 7 years of follow-up, assured by two memory experts based on best clinical practice and validated criteria, were obtained. Multivariate logistic regression models assessed the association of percent change in AMM and FM with risk of cognitive dysfunction. RESULTS At 7 years of follow-up, 15 participants suffered from dementia, 6 suffered from mild cognitive impairment, and 160 were cognitively normal. Neither body composition changes nor gait speed was found to be statistically associated with cognitive dysfunction after controlling for potential confounders. Only age, over 85 years, was associated with an increased risk of subsequent cognitive impairment (odds ratio 3.10; 95 % confidence interval 1.07-8.87). CONCLUSIONS No significant association could be evidenced between changes in body composition and cognitive dysfunction. Due to the small sample size, statistical power could be an issue. The study could also suggest the possibility that the risk of cognitive dysfunction is not mediated by changes in body composition.
Collapse
Affiliation(s)
- Gabor Abellan van Kan
- Gérontopôle de Toulouse, Department of Geriatric Medicine, Toulouse University Hospital, 170, Avenue de Casselardit, 31059, Toulouse, France,
| | | | | | | | | | | |
Collapse
|
8
|
Kelaiditi E, Cesari M, Canevelli M, van Kan GA, Ousset PJ, Gillette-Guyonnet S, Ritz P, Duveau F, Soto ME, Provencher V, Nourhashemi F, Salvà A, Robert P, Andrieu S, Rolland Y, Touchon J, Fitten JL, Vellas B. Cognitive frailty: rational and definition from an (I.A.N.A./I.A.G.G.) international consensus group. J Nutr Health Aging 2013; 17:726-34. [PMID: 24154642 DOI: 10.1007/s12603-013-0367-2] [Citation(s) in RCA: 558] [Impact Index Per Article: 50.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/10/2023]
Abstract
The frailty syndrome has recently attracted attention of the scientific community and public health organizations as precursor and contributor of age-related conditions (particularly disability) in older persons. In parallel, dementia and cognitive disorders also represent major healthcare and social priorities. Although physical frailty and cognitive impairment have shown to be related in epidemiological studies, their pathophysiological mechanisms have been usually studied separately. An International Consensus Group on "Cognitive Frailty" was organized by the International Academy on Nutrition and Aging (I.A.N.A) and the International Association of Gerontology and Geriatrics (I.A.G.G) on April 16th, 2013 in Toulouse (France). The present report describes the results of the Consensus Group and provides the first definition of a "Cognitive Frailty" condition in older adults. Specific aim of this approach was to facilitate the design of future personalized preventive interventions in older persons. Finally, the Group discussed the use of multidomain interventions focused on the physical, nutritional, cognitive and psychological domains for improving the well-being and quality of life in the elderly. The consensus panel proposed the identification of the so-called "cognitive frailty" as an heterogeneous clinical manifestation characterized by the simultaneous presence of both physical frailty and cognitive impairment. In particular, the key factors defining such a condition include: 1) presence of physical frailty and cognitive impairment (CDR=0.5); and 2) exclusion of concurrent AD dementia or other dementias. Under different circumstances, cognitive frailty may represent a precursor of neurodegenerative processes. A potential for reversibility may also characterize this entity. A psychological component of the condition is evident and concurs at increasing the vulnerability of the individual to stressors.
Collapse
Affiliation(s)
- E Kelaiditi
- Eirini Kelaiditi, Institut du Vieillissement, Gérontopôle, Université de Toulouse III-Paul Sabatier. 37 Allées Jules Guesde, 31000 Toulouse, France. Phone: +33 (0) 56114-5668;
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
9
|
Gillette-Guyonnet S, Secher M, Vellas B. Nutrition and neurodegeneration: epidemiological evidence and challenges for future research. Br J Clin Pharmacol 2013; 75:738-55. [PMID: 23384081 DOI: 10.1111/bcp.12058] [Citation(s) in RCA: 107] [Impact Index Per Article: 9.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/16/2012] [Accepted: 11/20/2012] [Indexed: 12/15/2022] Open
Abstract
The prevention of dementias, such as Alzheimer's disease (AD), is a growing public health concern, due to a lack of effective curative treatment options and a rising global prevalence. Various potential risk or preventive factors have been suggested by epidemiological research, including modifiable lifestyle factors such as diet. Current epidemiological data are in favour of a protective role of certain micronutrients (B vitamins related to homocysteine metabolism, the anti-oxidant vitamins C and E, flavonoids, polyunsatured omega-3 fatty acids, vitamin D) and macronutrients (fish) in the prevention of cognitive decline and dementia/AD. Some factors have been targeted by interventions tested in randomized controlled trials (RCTs), but many of the results are conflicting with observational evidence. Epidemiological analysis of the relations between nutrient consumption and cognitive decline is complex and it is highly unlikely that a single component plays a major role. In addition, since multiple factors across the life course influence brain function in late life, multidomain interventions might be more promising in the prevention of cognitive decline and dementia/AD. Designing such trials remains very challenging for researchers. The main objective of this paper is to review the epidemiologic data linking potential protective factors to cognitive decline or dementia/AD, focusing particularly on the roles of adiposity, caloric restriction, micro (group B vitamins related to homocysteine metabolism, the anti-oxidant vitamins C and E, flavonoids, polyunsatured omega-3 fatty acids, vitamin D) and macronutrients (fish). Limitations of the current data, divergence with results of interventional prevention studies and challenges for future research are discussed.
Collapse
Affiliation(s)
- Sophie Gillette-Guyonnet
- Gerontopole, Toulouse University Hospital, Department of Internal Medicine and Geriatrics, Purpan University Hospital, Toulouse F-31059, France.
| | | | | |
Collapse
|
10
|
Vellas B, Balardy L, Gillette-Guyonnet S, Abellan Van Kan G, Ghisolfi-Marque A, Subra J, Bismuth S, Oustric S, Cesari M. Looking for frailty in community-dwelling older persons: the Gérontopôle Frailty Screening Tool (GFST). J Nutr Health Aging 2013; 17:629-31. [PMID: 23933875 DOI: 10.1007/s12603-013-0363-6] [Citation(s) in RCA: 145] [Impact Index Per Article: 13.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
Abstract
The frailty syndrome is a pre-disability condition suitable to be targeted by preventive interventions against disability. In order to identify frail older persons at risk of negative outcomes, general practitioners must be provided with an easy and quick screening tool for detecting frailty without special effort. In the present paper, we present the screening tool for frailty that the Gérontopôle of Toulouse (France) has developed and implemented in primary care in the region with the collaboration of the Department of Family Medicine of the University of Toulouse. The Gérontopôle Frailty Screening Tool (GFST) is designed to be administered to persons aged ≥65 years with no physical disability and acute clinical disease. It is composed by an initial questionnaire aimed at attracting the general practitioner's attention to very general signs and/or symptoms suggesting the presence of an underlying frailty status. Then, in a second section, the general practitioner expresses his/her own view about the frailty status of the individual. The clinical judgment of the general practitioner is finally retained for determining the eventual presence of frailty. Preliminary data document that almost everyone (95.2%) of the 442 patients referred to the Gérontopôle frailty clinic by general practitioners using the GFST indeed presents a condition of (pre-)frailty according to the criteria proposed by Fried and colleagues in the Cardiovascular Health Study. The use of the GFST may help at raising awareness about the importance of identifying frailty, training healthcare professionals at the detection of the syndrome, and developing preventive interventions against disabling conditions.
Collapse
Affiliation(s)
- B Vellas
- Gérontopôle, Centre Hspitalier Universitaire De Toulouse, Toulouse, France
| | | | | | | | | | | | | | | | | |
Collapse
|
11
|
Abellan van Kan G, Cesari M, Gillette-Guyonnet S, Dupuy C, Nourhashémi F, Schott AM, Beauchet O, Annweiler C, Vellas B, Rolland Y. Sarcopenia and cognitive impairment in elderly women: results from the EPIDOS cohort. Age Ageing 2013; 42:196-202. [PMID: 23221099 DOI: 10.1093/ageing/afs173] [Citation(s) in RCA: 84] [Impact Index Per Article: 7.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/13/2022] Open
Abstract
BACKGROUND common pathophysiological pathways are shared between age-related body composition changes and cognitive impairment. OBJECTIVE evaluate whether current operative sarcopenia definitions are associated with cognition in community-dwelling older women. DESIGN cross-sectional analyses. SUBJECTS a total of 3,025 women aged 75 years and older. MEASUREMENTS body composition (assessed by dual energy X-ray absorptiometry) and cognition (measured by short portable mental status questionnaire) were obtained in all participants. Multivariate logistic regression models assessed the association of six operative definitions of sarcopenia with cognitive impairment. Gait speed (GS, measured over a 6-meter track at usual pace) and handgrip strength (HG, measured by a hand-held dynamometer) were considered additional factors of interest. RESULTS a total of 492 (16.3%) women were cognitively impaired. The prevalence of sarcopenia ranged from 3.3 to 18.8%. No sarcopenia definition was associated with cognitive impairment after controlling for potential confounders. To proof consistency, the analyses were performed using GS and HG, two well-established predictors of cognitive impairment. Low GS [odds ratio (OR) 2.42, 95% confidence interval (CI) 1.72-3.40] and low HG (OR: 1.81, 95% CI: 1.33-2.46) were associated with cognitive impairment. CONCLUSION no significant association was evidenced between different operative sarcopenia definitions and cognitive impairment. The study suggests that the association between physical performance and cognitive impairment in not mediated by sarcopenia.
Collapse
Affiliation(s)
- Gabor Abellan van Kan
- Gérontopôle de Toulouse, Department of Geriatric Medicine, Toulouse University Hospital, 170, avenue de Casselardit, Toulouse 31059, France.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
12
|
Rolland Y, Tavassoli N, Gillette-Guyonnet S, Perrin A, Hermabessière S, Ousset PJ, Nourhashemi F, Cestac P, Vellas B. Multidisciplinary team meetings (MDTM) in detection of Alzheimer's disease: data from the IDEM study. J Nutr Health Aging 2013; 17:137-41. [PMID: 23364491 DOI: 10.1007/s12603-012-0403-7] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
Abstract
INTRODUCTION The National Institute for Health and Clinical Excellence (NICE) in the United Kingdom, the Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWIG) in Germany and the Haute Autorité de Santé (HAS) in France have recently set out guidelines on prescription of anti-dementia medication. The HAS proposes in particular that continuation of these drugs for longer than one year should be decided in multidisciplinary team meetings (MDTM). OBJECTIVE To assess the feasibility of MDTM and the satisfaction of coordinating physicians from institutions for the dependent elderly (nursing home, NH) and expert physicians from memory clinics who have participated in the meetings. METHODS Survey carried out among physicians who had participated in the MDTM held as part of the IDEM study (Interest of systematic tracking of dementia cases in NH: analysing the contribution of MDTM in Alzheimer's disease and related diseases; PHRC National 2009, Code 0910701). The survey evaluated the organization of MDTM and the physicians' opinion of these meetings. RESULTS The cases of 574 patients were discussed in MDTM involving 133 healthcare professionals (32 coordinating physicians, 48 expert physicians, 4 general practitioners and 49 other health professionals). The mean number of participants was 4.2±1.6. About 16 minutes were spent discussing the case of each resident. About 90% of physicians considered that the meetings were useful. Overall assessment of their efficacy was 11.5/20 for the coordinating physicians and 14.1/20 for the expert physicians. The benefits of MDTM in relation to the work entailed were considered important by 60% of expert physicians and 33% of coordinating physicians. CONCLUSIONS Our survey confirmed the feasibility of MDTM in the field of Alzheimer's disease. The overall benefit/workload ratio of the meetings was considered to be favorable for the expert physicians. The benefits of MDTM were turned out to be less appreciated by the coordinating physicians according to high workload involved.
Collapse
Affiliation(s)
- Y Rolland
- Gérontopôle de Toulouse, Département de Médecine Interne et Gérontologie Clinique, Centre Hospitalo-Universitaire de Toulouse, Toulouse, France.
| | | | | | | | | | | | | | | | | |
Collapse
|
13
|
Costa N, Ferlicoq L, Derumeaux-Burel H, Rapp T, Garnault V, Gillette-Guyonnet S, Andrieu S, Vellas B, Lamure M, Grand A, Molinier L. Comparison of informal care time and costs in different age-related dementias: a review. Biomed Res Int 2012; 2013:852368. [PMID: 23509789 PMCID: PMC3591240 DOI: 10.1155/2013/852368] [Citation(s) in RCA: 33] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 07/12/2012] [Revised: 10/25/2012] [Accepted: 10/25/2012] [Indexed: 11/17/2022]
Abstract
OBJECTIVES Age-related dementia is a progressive degenerative brain syndrome whose prevalence increases with age. Dementias cause a substantial burden on society and on families who provide informal care. This study aims to review the relevant papers to compare informal care time and costs in different dementias. METHODS A bibliographic search was performed on an international medical literature database (MEDLINE). All studies which assessed the social economic burden of different dementias were selected. Informal care time and costs were analyzed in three care settings by disease stages. RESULTS 21 studies met our criteria. Mean informal care time was 55.73 h per week for Alzheimer disease and 15.8 h per week for Parkinson disease (P = 0.0076), and the associated mean annual informal costs were $17,492 versus $3,284, respectively (P = 0.0393). CONCLUSION There is a lack of data about informal care time and costs among other dementias than AD or PD. Globally, AD is the most costly in terms of informal care costs than PD, $17,492 versus $3,284, respectively.
Collapse
|
14
|
Subra J, Gillette-Guyonnet S, Cesari M, Oustric S, Vellas B. The integration of frailty into clinical practice: preliminary results from the Gérontopôle. J Nutr Health Aging 2012; 16:714-20. [PMID: 23076514 DOI: 10.1007/s12603-012-0391-7] [Citation(s) in RCA: 95] [Impact Index Per Article: 7.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/10/2023]
Abstract
BACKGROUND Disability is commonly considered as an irreversible condition of advanced age. Therefore, preventive actions need to be taken before the disabling cascade is fully established, that is in the pre-disability phase defined "frailty syndrome". The complexity and heterogeneity of frailty requires a clinical approach based on multidimensionality and multidisciplinary. In this paper, we present the main characteristics of the newborn Platform for Evaluation of Frailty and Prevention of Disability (Toulouse, France). INTERVENTION Persons aged 65 years and older screened for frailty by general practitioners in the Toulouse area are invited to undergo a multidisciplinary evaluation at the Platform. Here, the individual is multidimensionality assessed in order to preventively detect potential risk factors for disability. At the end of the comprehensive evaluation, the team members propose the patient (in agreement with the general practitioner) a preventive intervention program specifically tailored to the his/her needs and resources. RESULTS Mean age of our population is 82.7 years, with a large majority aged 75 years and older. Most patients are women (61.9%) Approximately two thirds of patients received any kind of regular help. Regarding level of frailty, 65 patients (41.4%) were pre-frail, and 83 (52.9%) frail. For what concerns the functional status, 83.9% of patients presented slow gait speed, 53.8% were sedentary, and 57.7% had poor muscle strength. Only 27.2% of patients had a SPPB score equal to or higher than 10. Autonomy in ADL was quite well preserved (mean ADL score 5.6 ± 0.8) as expected, suggesting that the patients of the platform have not yet developed disability. Consistently, IADL showed a marginal loss of autonomy reporting a mean score of 6.0 ± 2.3. About one third of patients (33.1%) presented a MMSE score lower than 25. Dementia (measured by the CDR scale) was observed in 11.6% of the platform population, whereas subjects with mild cognitive impairment (that is CDR equal to 0.5) were 65.8%. New diagnosed depressive disorders were relatively rare with only 3.2% of patients showing signs of depression but some people were already treated. Numerous patients presented vision problems with 10.4% having abnormal findings at the Amsler grid. Finally, it is noteworthy that 9% of the platform population presented an objective state of protein-energy malnutrition, 34% an early alteration of nutritional status, while almost everyone (94.9%) had a vitamin D deficiency (partially explained by the period of the year, that is winter-spring, of most of the measurements). CONCLUSION The Platform clinically evaluates and intervenes on frailty for the first time at the general population-level. This model may serve as preliminary step towards a wider identification of early signs of the disabling cascade in order to develop more effective preventive interventions.
Collapse
Affiliation(s)
- J Subra
- University Department of General Medicine, 133 route de narbonne, 31062 Toulouse Cedex, France
| | | | | | | | | |
Collapse
|
15
|
Abstract
The formation of the first Gerontopole in Toulouse was a response to a mission letter sent by French Ministers of Health on February 2007. The mission of the Toulouse Gerontopole is based around three major axes: 1) To facilitate the access of frail elderly people to innovative therapy and clinical research: the Gérontopôle set up the national network for clinical investigation into Alzheimer's disease (AD) funded through the CeNGEPS (National Centre For Management of Trials on Health Products) calls for proposals since July 2008. In addition, the Gérontopôle coordinates several national clinical trials with promising drugs with potential effect on the mechanisms and evolution of AD and actively participates in studies on biomarkers; 2) To develop health promotion actions and prevention trials for healthy elderly people, through the Institute of Aging: the Gérontopôle has implemented the GuidAge (Phase III trial concerning the efficiency of Ginkgo Biloba on the impact and delay of appearance of an Alzheimer type dementia) and MAPT (Multi-domain Alzheimer Preventive Trial) studies on prevention of AD and cognitive decline. It is curently working on the new generation of preventive trials based on biomarkers; 3) To develop clinical research for dependant elderly people, through the implementation of the REHPA research network including 240 nursing homes in France. In December 2009, additional grants were delivered by the French government to extend the three research axes for two more years, and establish a charter of quality for geriatric care in relation with the administration and relevant agencies.
Collapse
Affiliation(s)
- Sophie Gillette-Guyonnet
- Gerontopole, Toulouse University Hospital, Department of Internal Medicine and Geriatrics, Purpan University Hospital, Toulouse, France.
| | | |
Collapse
|
16
|
Carrié I, van Kan GA, Gillette-Guyonnet S, Andrieu S, Dartigues JF, Touchon J, Dantoine T, Rouaud O, Bonnefoy M, Robert P, Cuffi MN, Bories L, Bordes S, Gasnier Y, Desclaux F, Sudres K, Pesce A, Vellas B. Recruitment strategies for preventive trials. The MAPT study (MultiDomain Alzheimer Preventive Trial). J Nutr Health Aging 2012; 16:355-9. [PMID: 22499458 DOI: 10.1007/s12603-012-0046-8] [Citation(s) in RCA: 45] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
Abstract
1680 participants were randomized over the recruitment period in MAPT study. A total of 1290 participants were recruited in the 7 University Hospital centers, and 390 participants in the 6 memory clinics around Toulouse Gerontopole / Alzheimer Disease research clinical center. The first randomization was on May 30, 2008, and the targeted number of randomized participants was reached on February 24, 2011; 2595 subjects were finally screened, of which 1680 fulfilled the eligibility criteria which represents 64.8%. Approximately, one quarter of screened people refused to participate after the detailed presentation of the study and 4.3% were still interested in participating but missed for unknown reasons the baseline visit even after repeated contacts. Of the 1810 subjects who signed the consent for participating to the study at the baseline visit, 130 (7.1%) were excluded because one of the eligibility criteria was not satisfied. Interestingly, the higher percentage of randomizations compared to screened participants is the personal contact source; almost 85 % of screened participants entered in the study. In an equivalent way, Medias and conferences are efficient recruiting sources to enrol volunteers in the study. Unexpectedly, only about 60% of screened participants from the hospital and GP sources were randomized and 33.2% from health care services. Almost a quarter of the randomized participants come from the hospital outpatients clinics and approximately 20% from public conferences. A total of 1128 contacts yielded to 556 screened volunteers and 345 randomized participants in the coordinating center of Toulouse. Thus, 30 % of contacts were recruited.
Collapse
Affiliation(s)
- I Carrié
- Gérontopôle, Departement of Geriatrics, CHU Toulouse, Purpan University Hospital, Toulouse, France
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
17
|
Gillette-Guyonnet S, Andrieu S, Nourhashemi F, Gardette V, Coley N, Cantet C, Gauthier S, Ousset PJ, Vellas B. Long-term progression of Alzheimer's disease in patients under antidementia drugs. Alzheimers Dement 2012; 7:579-92. [PMID: 22055975 DOI: 10.1016/j.jalz.2011.02.009] [Citation(s) in RCA: 47] [Impact Index Per Article: 3.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/29/2010] [Revised: 01/13/2011] [Accepted: 02/08/2011] [Indexed: 11/17/2022]
Abstract
BACKGROUND Patients with Alzheimer's disease (AD), even in the presence of symptomatic relief from medical intervention, face a persistent worsening of cognitive decline and performance in activities of daily living. Data regarding the long-term disease progression outside of therapeutic trials are lacking. We examined the effects of standard of care for AD patients on the prognosis of the disease in a real-life study over a 4-year period. METHODS A total of 686 patients with mild-moderate AD were enrolled in 16 memory clinics (REseau sur la maladie d' Alzheimer FRançais [REAL.FR] cohort) and followed up twice annually with tools used in therapeutic trials (Mini-Mental Status Examination, Alzheimer Disease Assessment Scale-cognitive subscale [ADAS-cog]: cognitive function, Clinical Dementia Rating: dementia severity, Activity of Daily Living [ADL]: incapacities, NeuroPsychiatric Inventory: neuropsychiatric symptom). RESULTS More than 90% of the patients used AD-specific medication over 4 years. Patients lost on average 2.4 points per year on the Mini-Mental Status Examination and gained 4.5 points on the ADAS-cog. ADL and NeuroPsychiatric Inventory scores became significantly worse over time. Incidence of incapacities for ADL and worsening of neuropsychiatric symptoms were 52.5 (95% confidence interval [CI]: 47.7-57.4) and 51.1 (95% CI: 46.2-56.1), respectively. Rates of mortality and institutionalization were 7.4 (95% CI: 6.2-8.5) and 13.4 (95% CI: 11.7-15.1). In all, 17% of patients in mild stage at baseline (Clinical Dementia Rating = 0.5) did not experience a major event (functional disabilities, neuropsychiatric symptoms, or death) over a 4-year period. CONCLUSIONS As compared with previous surveys, the current study shows slower rates of decline in AD patients. The present data also underline the high level of variability of disease progression among AD patients. Outcome measures commonly used in clinical trials will need to take into account the recent changes in the prognosis of the disease.
Collapse
Affiliation(s)
- Sophie Gillette-Guyonnet
- Department of Internal Medicine and Geriatrics, Purpan University Hospital, Gerontopole Toulouse University Hospital, France.
| | | | | | | | | | | | | | | | | |
Collapse
|
18
|
Soto ME, Secher M, Gillette-Guyonnet S, van Kan GA, Andrieu S, Nourhashemi F, Rolland Y, Vellas B. Weight Loss and Rapid Cognitive Decline in Community-Dwelling Patients with Alzheimer's Disease. ACTA ACUST UNITED AC 2012; 28:647-54. [DOI: 10.3233/jad-2011-110713] [Citation(s) in RCA: 90] [Impact Index Per Article: 7.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
Affiliation(s)
- Maria E. Soto
- Alzheimer's Disease Research and Clinical Centre, Department of Geriatric Medicine, Gérontopôle, Toulouse University Hospital, Toulouse, France
- Inserm U 1027, Toulouse, France
| | - Marion Secher
- Alzheimer's Disease Research and Clinical Centre, Department of Geriatric Medicine, Gérontopôle, Toulouse University Hospital, Toulouse, France
- University of Toulouse III, Toulouse, France
| | - Sophie Gillette-Guyonnet
- Alzheimer's Disease Research and Clinical Centre, Department of Geriatric Medicine, Gérontopôle, Toulouse University Hospital, Toulouse, France
- Inserm U 1027, Toulouse, France
| | - Gabor Abellan van Kan
- Alzheimer's Disease Research and Clinical Centre, Department of Geriatric Medicine, Gérontopôle, Toulouse University Hospital, Toulouse, France
- Inserm U 1027, Toulouse, France
| | - Sandrine Andrieu
- Inserm U 1027, Toulouse, France
- University of Toulouse III, Toulouse, France
- Department of Epidemiology and Public Health, Toulouse University Hospital, Toulouse, France
| | - Fati Nourhashemi
- Alzheimer's Disease Research and Clinical Centre, Department of Geriatric Medicine, Gérontopôle, Toulouse University Hospital, Toulouse, France
- Inserm U 1027, Toulouse, France
- University of Toulouse III, Toulouse, France
| | - Yves Rolland
- Alzheimer's Disease Research and Clinical Centre, Department of Geriatric Medicine, Gérontopôle, Toulouse University Hospital, Toulouse, France
- Inserm U 1027, Toulouse, France
- University of Toulouse III, Toulouse, France
| | - Bruno Vellas
- Alzheimer's Disease Research and Clinical Centre, Department of Geriatric Medicine, Gérontopôle, Toulouse University Hospital, Toulouse, France
- Inserm U 1027, Toulouse, France
- University of Toulouse III, Toulouse, France
| |
Collapse
|
19
|
|
20
|
Abellan van Kan G, Rolland Y, Gillette-Guyonnet S, Gardette V, Annweiler C, Beauchet O, Andrieu S, Vellas B. Gait speed, body composition, and dementia. The EPIDOS-Toulouse cohort. J Gerontol A Biol Sci Med Sci 2011; 67:425-32. [PMID: 21975092 DOI: 10.1093/gerona/glr177] [Citation(s) in RCA: 67] [Impact Index Per Article: 5.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/25/2022] Open
Abstract
BACKGROUND Slow gait speed (GS) predicts dementia, but this association might be mediated by body composition parameters like total fat mass (TFM) or total lean mass (TLM). The aim of the study was to evaluate whether GS, TLM, and TFM were associated factors with an increased risk for subsequent dementia in community-dwelling older women. METHODS A case-control study was nested in the EPIDemiologie de l'OStéoporose cohort. GS (at usual pace more than 6 m), TLM, and TFM (assessed by dual energy x-ray absorptiometry) were measured at baseline. Cognitive performance was evaluated at baseline and at 7 years of follow-up. The presence of dementia was assured by two blinded memory experts based on best practice and validated criteria. Multivariate logistic regression models assessed the association of GS, TLM, and TFM with dementia risk. RESULTS Of the initial 1,462 women, 75 years old and older, 647 (43.4%) were cognitively intact at baseline and had a full cognitive assessment at 7 years (145 of them developed dementia). Controlled for covariates (demographics, physical activity, self-reported disabilities, and comorbidities), GS was an independent associated factor for subsequent dementia as a continuous variable (odds ratio [OR] 2.28, 95% CI: 1.32-3.94) and as a categorized variable (OR 2.38, 95% CI: 1.28-4.43 highest vs lowest quartile). Neither interaction with GS nor a statistically significant association with dementia risk was found for TLM and TFM. CONCLUSIONS GS was an independent associated factor for subsequent dementia not mediated by TLM or TFM.
Collapse
|
21
|
Andrieu S, Aboderin I, Baeyens JP, Beard J, Benetos A, Berrut G, Brainin M, Cha HB, Chen LK, Du P, Forette B, Forette F, Franco A, Fratiglioni L, Gillette-Guyonnet S, Gold G, Gomez F, Guimaraes R, Gustafson D, Khachaturian A, Luchsinger J, Mangialasche F, Mathiex-Fortunet H, Michel JP, Richard E, Schneider LS, Solomon A, Vellas B. IAGG workshop: health promotion program on prevention of late onset dementia. J Nutr Health Aging 2011; 15:562-75. [PMID: 21808935 DOI: 10.1007/s12603-011-0142-1] [Citation(s) in RCA: 20] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/17/2022]
Abstract
IAGG, WHO, and SFGG organized a international workshop on Health promotion programs on prevention of late on-set dementia. Thirty world specialists coming from Europe, North America, Asia, South America, Africa and Australia, shared their experience on methods and results of large epidemiological interventions to reduce incidents of dementia or delay its on-set. Chaired by Laura FRATIGLIONI, an expert in Epidemiological studies on dementia issues, the workshop gave opportunity for discussions and controversies about the state-of-the-art. Based on different national and international trials (ADAPT, MAPT, FINGER, GUDIAGE, GEM etc) the questions remained opened for different aspects of methodology, the choice of domain or multi domain intervention, the choice and the definition of the target populations, the best age of candidates, the issues related to the discrepancy between late effects, and interventions' duration. We are please to publish in the Journal, the presentations presented to this workshop. These publications will complete previously task force published in the journal in the last two years on methodological issues for Alzheimer's trials including end point, biomarkers, and the experience of past therapeutic trials.
Collapse
Affiliation(s)
- S Andrieu
- Professor of Public Health at the Toulouse University Hospital and is Head of the Aging and Alzheimer Disease research team, France
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
22
|
Coley N, Gardette V, Cantet C, Gillette-Guyonnet S, Nourhashemi F, Vellas B, Andrieu S. How Should We Deal with Missing Data in Clinical Trials Involving Alzheimers Disease Patients? Curr Alzheimer Res 2011; 8:421-33. [PMID: 21244348 DOI: 10.2174/156720511795745339] [Citation(s) in RCA: 21] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/29/2010] [Accepted: 11/15/2010] [Indexed: 11/22/2022]
|
23
|
Coley N, Gardette V, Cantet C, Gillette-Guyonnet S, Nourhashemi F, Vellas B, Andrieu S. How Should We Deal with Missing Data in Clinical Trials Involving Alzheimer's Disease Patients? Curr Alzheimer Res 2011. [DOI: 10.2174/1567211212443482050] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
|
24
|
Rolland Y, Abellan Van Kan G, Gillette-Guyonnet S, Roux C, Boonen S, Vellas B. Strontium ranelate and risk of vertebral fractures in frail osteoporotic women. Bone 2011; 48:332-8. [PMID: 20817053 DOI: 10.1016/j.bone.2010.08.022] [Citation(s) in RCA: 23] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/02/2010] [Revised: 08/13/2010] [Accepted: 08/30/2010] [Indexed: 11/22/2022]
Abstract
AIM Therapies to treat osteoporosis remain underutilized and minimally evaluated in frail elderly patients. Our study determined and compared the risk of vertebral fractures in frail, intermediate and robust older patients being treated with strontium ranelate vs. placebo. METHODS Data were obtained from the SOTI (Spinal Osteoporosis Therapeutic Intervention) and TROPOS (Treatment Of Peripheral Osteoporosis) studies which randomized participants to receive either strontium ranelate or placebo over 3 years. Frail, intermediate and robust patients were identified using adapted Fried's criteria. Analyses were performed according to the intention-to-treat principle utilizing 1- and 3-year study follow-up data. RESULTS 2346 robust, 2472 intermediate and 264 frail women were identified. At 3 years, the risk for vertebral fractures was reduced by 30% (Relative Risk [RR], 0.70; 95% confidence interval [CI], 0.57-0.86) in the robust, by 45% (RR, 0.55; 95%CI, 0.46-0.67) in the intermediate and by 58% (RR, 0.42; 95%CI, 0.24-0.74) in the frail patients compared to those assigned to placebo (p<0.01 for all three groups; p=0.11 for trend). Risk of vertebral fracture was significantly reduced within 1 year in all three groups. Numbers of subjects needed to be treated to prevent one new vertebral fracture over 3 years were 13, 9 and 5 in the robust, intermediate and frail groups, respectively. Adverse event profiles and medication compliance were similar across the 3 groups. CONCLUSIONS The imperative to treat osteoporosis appears to be greatest in frail patients since similar relative risk reductions would avert more fractures in frail than in non-frail elderly patients.
Collapse
Affiliation(s)
- Yves Rolland
- Inserm U558, F-31073, Avenue Jules Guesdes, University of Toulouse III, F-31073, France.
| | | | | | | | | | | |
Collapse
|
25
|
Abstract
PURPOSE OF REVIEW The review summarizes and discusses the proposed new definitions for sarcopenia and cachexia. It also highlights the overlapping of both conditions and the fact that these conditions frequently occur in elderly patients. RECENT FINDINGS Sarcopenia is now recognized as a multifactorial geriatric syndrome. Cachexia is defined as a metabolic syndrome in which inflammation is the key feature and so cachexia can be an underlying condition of sarcopenia. Recently, cachexia has been defined as 'a complex metabolic syndrome associated with underlying illness and characterized by loss of muscle mass with or without loss of fat mass. The prominent clinical feature of cachexia is weight loss in adults'. Different recommendations have been proposed for the diagnosis of sarcopenia. At present, all definitions combine an assessment of muscle mass and muscle function (strength or physical performances such as gait speed). However, the relevance and the validation of these evolving definitions need to be assessed in future studies. SUMMARY Although the recent definitions of sarcopenia and cachexia boost research in the field and define distinct entities, the cause behind the loss of muscle mass (whether cachexia or sarcopenia) may, however, be indistinguishable in clinical practice. Therefore, new therapeutic approaches, alone or in combination, could be targeted on both conditions.
Collapse
Affiliation(s)
- Yves Rolland
- Inserm U558, University of Toulouse III, France.
| | | | | | | |
Collapse
|
26
|
Abstract
No clear consensual definition regarding frailty seems to emerge from the literature after 30 years of research in the topic, and a large array of models and criteria has been proposed to define the syndrome. Controversy continues to exist on the choice of the components to be included in the frailty definition. Two main definitions based on clusters of components are found in literature: a physical phenotype of frailty, operationalized in 2001 by providing a list of 5 measurable items of functional impairments, which coexists with a multidomain phenotype, based on a frailty index constructed on the accumulation of identified deficits based on comprehensive geriatric assessment. The physical phenotype considers disability and comorbidities such as dementia as distinct entities and therefore outcomes of the frailty syndrome, whereas comorbidity and disability can be components of the multidomain phenotype. Expanded models of physical frailty (models that included clusters other than the original 5 items such as dementia) increased considerably the predicting capacity of poor clinical outcomes when compared with the predictive capacity of the physical phenotype. The unresolved controversy of the components shapes the clusters of original frailty syndrome, and the components depend very much on how frailty is defined. This update also highlights the growing evidence on gait speed to be considered as a single-item frailty screening tool. The evaluation of gait speed over a short distance emerges from the literature as a tool with the capacity to identify frail older adults, and slow gait speed has been proven to be a strong predictor for frailty-adverse outcomes.
Collapse
Affiliation(s)
- Gabor Abellan van Kan
- Gérontopôle de Toulouse, Department of Geriatric Medicine, Pavillon JP Junod, University Hospital Toulouse, CHU Toulouse, 170 Avenue de Casselardit, TSA 40031, 31059 Toulouse Cedex 9, France.
| | | | | | | | | | | |
Collapse
|
27
|
Nourhashemi F, Andrieu S, Gillette-Guyonnet S, Giraudeau B, Cantet C, Coley N, Vellas B. Effectiveness of a specific care plan in patients with Alzheimer's disease: cluster randomised trial (PLASA study). BMJ 2010; 340:c2466. [PMID: 20522656 PMCID: PMC2881198 DOI: 10.1136/bmj.c2466] [Citation(s) in RCA: 41] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/18/2022]
Abstract
OBJECTIVE To test the effectiveness of a comprehensive specific care plan in decreasing the rate of functional decline in patients with mild to moderate Alzheimer's disease compared with usual care in memory clinics. DESIGN Cluster randomised trial. SETTING 50 memory clinics in France. PARTICIPANTS Patients with Alzheimer's disease (mini-mental state examination score 12-26). 1131 patients were included: 574 from 26 clinics in the intervention group, and 557 from 24 clinics in the usual care (control) group. Memory clinics were the unit of randomisation. INTERVENTION The intervention included a comprehensive standardised twice yearly consultation for patients and their caregivers, with standardised guidelines for the management of problems identified during the assessment. MAIN OUTCOME MEASURES The primary outcome measure was change on the Alzheimer's Disease Cooperative Study-activities of daily living scale assessed at 12 and 24 months. Secondary outcome measures were the rate of admission to institutional care and mortality. RESULTS At two years the assessment was completed by 58.4% (n=335) of patients in the intervention group and 61.6% (n=343) in the control group. The rate of functional decline at two years did not differ between the groups. The annual rate of change on the Alzheimer's Disease Cooperative Study-activities of daily living was estimated at -5.73 (95% confidence interval -6.89 to -4.57) in the intervention group and -5.96 (-7.05 to -4.86) in the control group (P=0.78). CONCLUSION A comprehensive specific care plan in memory clinics had no additional positive effect on functional decline in patients with mild to moderate Alzheimer's disease. Future research should aim to determine the effects of more direct involvement of general practitioners. TRIAL REGISTRATION ClinicalTrials.gov NCT00480220.
Collapse
|
28
|
Abstract
Polyunsaturated fatty acids (PUFA) play a crucial role in cerebral structure and function. Omega-3 PUFA is an exciting area of research, with docosahexaenoic acid (DHA) emerging as a new potential agent for prevention of cognitive decline and treatment of Alzheimer's disease. Preclinical studies suggest that DHA maintains membrane fluidity, improves synaptic and neurotransmitter functioning, enhances learning and memory performances and displays neuroprotective properties. Several epidemiological studies supported the association between Omega-3 PUFA consumption and a lower prevalence of dementia. Although data are divergent, a growing body of evidence supports the view that regular consumption of dietary fish and seafood (which are rich in omega-3 PUFA) prevents cognitive decline. Finally, at present, few data are available from randomized clinical trials (RCTs). on the association between cognition and Omega-3. Ongoing RCTs that assess the effect of Omega-3 might provide new evidence on prevention and treatment of dementia. In this review, we summarize preclinical and clinical research suggesting that DHA exerts beneficial effects on cognitive function with ageing.
Collapse
Affiliation(s)
- I Carrié
- Gérontopôle, CHU Toulouse, Department of Geriatric Medicine, Toulouse, France.
| | | | | | | | | |
Collapse
|
29
|
Gillioz AS, Villars H, Voisin T, Cortes F, Gillette-Guyonnet S, Andrieu S, Gardette V, Nourhashémi F, Ousset PJ, Jouanny P, Vellas B. Spared and impaired abilities in community-dwelling patients entering the severe stage of Alzheimer's disease. Dement Geriatr Cogn Disord 2010; 28:427-32. [PMID: 19907179 DOI: 10.1159/000255635] [Citation(s) in RCA: 20] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Accepted: 08/25/2009] [Indexed: 11/19/2022] Open
Abstract
BACKGROUND Comprehensive geriatric assessments of patients entering the severe stage of Alzheimer's disease (AD) are scarce. METHODS Cross-sectional study of 126 patients entering the severe stage of AD in the longitudinal study of REAL.FR cohort. Patients who had a first MMSE score <10 during follow-up underwent cognitive, behavioral, nutritional and functional assessment. Support requirements were also evaluated. RESULTS The best-preserved cognitive abilities were social interaction and response to own name, while praxis, orientation, memory and language showed the largest declines. Regarding independence in daily living, locomotion was best preserved (71% of patients independent) while personal hygiene deteriorated most (15.5%). Behavioral disorders were frequent, and consisted principally of apathy, aberrant motor behavior, and agitation. The Mini Nutritional Assessment showed that 68.5% of patients were malnourished or at risk of malnutrition. Caregiver burden remained mild to moderate in 69.8% of cases. In addition, 80% of patients still lived at home and 71.6% used at least 2 support services, consisting mainly of physician visits and home help. CONCLUSION Assessment of remaining cognitive, functional abilities and behavioral disorders at entry to severe AD should help to improve targeted management aimed at preserving these abilities and treating complications, thereby optimizing these patients' quality of life.
Collapse
Affiliation(s)
- Anne-Sophie Gillioz
- Department of Geriatric Medicine, University Hospital Rennes, FR-35033 Rennes, France. anne-sophie.gillioz @ chu-rennes.fr
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
30
|
|
31
|
Guérin O, Andrieu S, Schneider SM, Cortes F, Cantet C, Gillette-Guyonnet S, Vellas B. Characteristics of Alzheimer's disease patients with a rapid weight loss during a six-year follow-up. Clin Nutr 2009; 28:141-6. [DOI: 10.1016/j.clnu.2009.01.014] [Citation(s) in RCA: 29] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/26/2008] [Revised: 01/12/2009] [Accepted: 01/26/2009] [Indexed: 10/21/2022]
|
32
|
Gillette-Guyonnet S, Andrieu S, Dantoine T, Dartigues JF, Touchon J, Vellas B. Commentary on “A roadmap for the prevention of dementia II. Leon Thal Symposium 2008.” The Multidomain Alzheimer Preventive Trial (MAPT): A new approach to the prevention of Alzheimer's disease. Alzheimers Dement 2009; 5:114-21. [DOI: 10.1016/j.jalz.2009.01.008] [Citation(s) in RCA: 59] [Impact Index Per Article: 3.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
Affiliation(s)
- Sophie Gillette-Guyonnet
- Gérontopôle de Toulouse; Department of Geriatrics; CHU Toulouse; Purpan University Hospital; Toulouse France
- INSERM U558; Toulouse France
- University Toulouse III; Toulouse France
| | - Sandrine Andrieu
- Gérontopôle de Toulouse; Department of Geriatrics; CHU Toulouse; Purpan University Hospital; Toulouse France
- INSERM U558; Toulouse France
- University Toulouse III; Toulouse France
- Department of Epidemiology and Public Health, Toulouse; CHU Toulouse; Toulouse France
| | - Thierry Dantoine
- CHU Limoges; Geriatrics Department; Limoges University Hospital; Limoges France
| | | | | | - B. Vellas
- Gérontopôle de Toulouse; Department of Geriatrics; CHU Toulouse; Purpan University Hospital; Toulouse France
- INSERM U558; Toulouse France
- University Toulouse III; Toulouse France
| | | |
Collapse
|
33
|
Nourhashémi F, Gillette-Guyonnet S, Rolland Y, Cantet C, Hein C, Vellas B. Alzheimer's disease progression in the oldest old compared to younger elderly patient: data from the REAL.FR study. Int J Geriatr Psychiatry 2009; 24:149-55. [PMID: 18613005 DOI: 10.1002/gps.2084] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Abstract
OBJECTIVE Although population-based studies have revealed marked increases in the prevalence and incidence of dementia, particularly in older age groups, longitudinal studies of cognitive change have been less frequently conducted. The aim of this study is to describe the progression of Alzheimer's disease (AD) in the oldest old (>or=85 years) and to compare it with the younger elderly. METHODS A cohort of 114 AD patients >or=85 years old and 572 AD patients <85 years living in the community at inclusion were monitored over 2 years in 16 centers of the French AD network (REAL.FR study). Each subject underwent extensive medical examination including functional (Activities of Daily Living or ADL) and neuropsychological evaluations (including Mini Mental Status Evaluation or MMSE) every 6 months. RESULTS The observed decrease in MMSE performance in patients >or=85 was -4.18 +/- 0.63 points during the 2-year follow-up (vs -4.62 +/- 0.25 in the younger group) with no statistically significant differences between the two groups. After adjusting for confounding factors, ADL score declined faster in the oldest old than in individuals <85 years old during the 2-year follow-up: -1.73 +/- 0.19 vs -1.27 +/- 0.08 (p = 0.0309). CONCLUSIONS Our study showed, that while the progression of cognitive impairment was identical in both groups, after adjustment for variables related both to age and dependency, the progression of dependency was more rapid in those over 85 years old.
Collapse
|
34
|
Soto ME, Andrieu S, Cantet C, Reynish E, Ousset PJ, Arbus C, Gillette-Guyonnet S, Nourhashémi F, Vellas B. Predictive value of rapid decline in mini mental state examination in clinical practice for prognosis in Alzheimer's disease. Dement Geriatr Cogn Disord 2008; 26:109-16. [PMID: 18617740 DOI: 10.1159/000144073] [Citation(s) in RCA: 34] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Accepted: 02/18/2008] [Indexed: 11/19/2022] Open
Abstract
BACKGROUND Given the poorer prognosis of Alzheimer's disease (AD) patients with rapid cognitive decline (RCD), there is a need for a clinical assessment tool to detect these patients. OBJECTIVE To investigate if there is a Mini Mental State Examination (MMSE) threshold of decline during 6 months of follow-up which predicts a worse disease progression at the 2-year follow-up. Then, to propose a feasible definition of RCD for routine clinical practice. METHODS Data from 565 community-dwelling AD patients recruited in a multi-centre prospective observational study were assessed. All patients had MMSE scores between 10 and 26 at inclusion and were followed up 6-monthly using a standardised clinical assessment. Patients were classified as rapid and non-rapid decliners according to 2 MMSE decline thresholds tested: >or=3 points and >or=4 points for decline over the first 6 months of the study. Worse disease outcome was defined as attainment of 1 of 4 clinical end points 18 months later: institutionalisation, death, increased physical dependence or worsening of behavioural and psychological symptoms. RESULTS 135 patients (23.9%) lost >or=3 points during the first 6 months of follow-up in the MMSE score and 77 patients (13.6%) lost >or=4 points. Patients with moderate disease and a loss of >or=4 points showed a significantly increased risk of mortality (HR = 5.6, 95% CI 2.0-15.9) and institutionalisation (HR = 3.8, 95% CI 1.8-8.1) at the 2-year follow-up. The same MMSE threshold was associated with a higher risk of physical decline (HR = 1.6, 95% CI 1.2-2.3). CONCLUSION The loss of >or=4 points in MMSE during the first 6 months of follow-up seems to be a predictor of worse clinical course, and thus it could be used to define the category of AD patients presenting a RCD.
Collapse
Affiliation(s)
- Maria E Soto
- Department of Geriatric Medicine, Toulouse University Hospital, Toulouse, France.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
35
|
Soto ME, Andrieu S, Arbus C, Ceccaldi M, Couratier P, Dantoine T, Dartigues JF, Gillette-Guyonnet S, Nourhashemi F, Ousset PJ, Poncet M, Portet F, Touchon J, Vellas B. Rapid cognitive decline in Alzheimer's disease. Consensus paper. J Nutr Health Aging 2008; 12:703-13. [PMID: 19043645 DOI: 10.1007/bf03028618] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 09/29/2022]
Abstract
The rate of cognitive decline in Alzheimer's disease (AD) varies considerably between individuals, with some subjects showing substantial deterioration and others showing little or no change over the course of the disease. These wide variations support the relatively new concept of Rapid Cognitive Decline (RCD). Patients with an accelerated rate of cognitive decline have showed to present a worse evolution in terms of mortality, loss of autonomy and institutionalisation. The conclusions from RCD studies conducted in the past years remain very heterogeneous and sometimes contradictory. This is possibly due to methodological differences, mainly the different "a priori" definitions of RCD used to identify rapid decliners. Consequently of this, there is considerable variation in reported frequency of patients with RCD which may vary from 9.5% to 54%. The lack of both consensus definition and consensual clinical assessment tools is one of the major barriers for establishing an appropriated management of rapid decliners in clinical practice. Presently, management of rapid decliners in AD remains to be a challenge waiting to better know predictive factors of a RCD. To date no specific guidelines exist to follow-up or to treat patients with this condition. This consensus paper proposes the loss of 3 points or greater in Mini-Mental State Examination (MMSE) during six months as an empirical definition of rapid cognitive decline to be used in routine medical practice and to be relevant for clinical-decision making in patients with mild to moderately-severe AD.
Collapse
Affiliation(s)
- M E Soto
- Department of Geriatric Medicine, Toulouse University Hospital, Toulouse, France
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
36
|
Abstract
PURPOSE OF REVIEW In addition to extending lifespan, animal research shows that specific diets benefit brain functioning. Indeed, it has been proven that caloric restriction prevents age-related neuronal damage. What are those mechanisms involved in the effects of caloric restriction on brain functioning? Could caloric restriction be proposed in the future to prevent or treat neurodegenerative disorders such as Alzheimer's disease? Is there a future for caloric restriction interventions in adults? RECENT FINDINGS Hypotheses linking caloric restriction to cognitive capability include anti-inflammatory mechanisms, reduction of neural oxidative stress, promotion of synaptic plasticity, induction of various stress and neurotrophic/neuroprotective factors. Caloric restriction may also prevent beta-amyloid neuropathology in Alzheimer transgenic models. Finally, both exercise and caloric restriction enhance neurogenesis via different mechanisms suggesting that their combination may decrease the risk of neurodegenerative disease. SUMMARY It is now well established that caloric restriction could be used to promote successful brain aging. Data from randomized controlled trials in humans are limited. No positive effect on cognitive impairment was found probably due to methodological limitations. The long-term effects of caloric restriction in adults must be clarified before engaging in such preventive strategy. Additional animal studies must be conducted in the future to test the effects of 'multidomain' interventions (caloric restriction plus regular exercise) on age-related cognitive decline.
Collapse
|
37
|
Cortes F, Nourhashémi F, Guérin O, Cantet C, Gillette-Guyonnet S, Andrieu S, Ousset PJ, Vellas B. Prognosis of Alzheimer's disease today: a two-year prospective study in 686 patients from the REAL-FR Study. Alzheimers Dement 2008; 4:22-9. [PMID: 18631947 DOI: 10.1016/j.jalz.2007.10.018] [Citation(s) in RCA: 66] [Impact Index Per Article: 4.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/02/2006] [Revised: 07/20/2007] [Accepted: 10/25/2007] [Indexed: 12/01/2022]
Abstract
BACKGROUND The aim of the present study was to describe the long-term evolution of Alzheimer's disease (AD) in a prospective cohort of patients under treatment with a close follow-up. METHODS Six hundred eighty-six AD patients from the French Network on AD (REAL-FR) were followed up and assessed every 6 months for 2 years. Cognitive, functional, behavioral, nutritional, and global status were evaluated by using Mini-Mental State Examination (MMSE), cognitive subscale of AD Assessment Scale (ADAS-cog), Activities of Daily Living scale (ADL), Neuropsychiatric Inventory (NPI), Mini-Nutritional Assessment (MNA), and Clinical Dementia Rating (CDR). RESULTS There were 85.13% of patients who were specifically treated for AD during their participation in the study. We observed significant changes (P < .0001) on MMSE, -4.57 +/- 0.23; ADAS-cog, 7.11 +/- 0.41; ADL, -1.32 +/- 0.07; NPI, 2.94 +/- 0.77; MNA, -0.81 +/- 0.17; and sum of boxes of the CDR (CDR-SB), 4.17 +/- 0.17. After 2 years, 10.79% (95% confidence interval [CI], 8.47 to 13.11) of the patients evolved twice as rapidly as the mean of the whole cohort on MMSE (loss, > or =9 points), 65.89% (95% CI, 62.34 to 69.44) reported a loss of 3 to 9 points, and 23.32% (95% CI, 20.16 to 26.46) were stable or improved (loss of -2 points maximum). Annual incidences for institutionalization, hospitalization, and death were 11.84% (95% CI, 9.76 to 13.92), 26.13% (95% CI, 22.52 to 29.74), and 5.95% (95% CI, 4.56 to 7.34), respectively. CONCLUSIONS In a recent large AD cohort mostly under treatment, AD evolution appeared to be variable, with high incidences for death or institutionalization and with 11.84% of the patients exhibiting a rapid cognitive decline, whereas one fourth of the cohort appeared in relatively stable condition, and two thirds had a moderate but significant evolution of the disease. More studies are needed to better understand these variations in patients' evolution.
Collapse
Affiliation(s)
- Frédéric Cortes
- Department of Internal Medicine and Clinical Gerontology, Centre Hospitalier Universitaire Purpan-Casselardit, Toulouse, France.
| | | | | | | | | | | | | | | | | |
Collapse
|
38
|
Coley N, Gardette V, Toulza O, Gillette-Guyonnet S, Cantet C, Nourhashemi F, Andrieu S, Grand A, Vellas B. Predictive factors of attrition in a cohort of Alzheimer disease patients. The REAL.FR study. Neuroepidemiology 2008; 31:69-79. [PMID: 18622142 DOI: 10.1159/000144087] [Citation(s) in RCA: 36] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/04/2008] [Accepted: 05/05/2008] [Indexed: 11/19/2022] Open
Abstract
BACKGROUND Attrition, i.e. patient dropout, can threaten the validity of results in longitudinal studies. The aim of this study was to identify patient and caregiver factors predictive of attrition in a cohort of Alzheimer disease (AD) patients. METHODS 686 patients with mild to moderate AD were included in the multicenter prospective REAL.FR study. Standardized gerontological evaluations were carried out twice yearly. Factors associated with attrition were assessed by survival analysis using a Cox proportional hazard model. RESULTS After 2 years, 278 (40.5%) patients had dropped out. Causes of attrition included refusal (20.9%), death (20.1%), institutionalization (19.8%), and loss to follow-up (19.8%). Attrition rates between each 6-month wave were constant at 12%. After adjustment, several independent factors remained associated with attrition: patients cared for by an unrelated caregiver [HR 1.7; 95% CI (1.08-2.59)], loss of autonomy [HR = 1.37; (1.03-1.82)], increasing caregiver burden [HR = 1.014; (1.005-1.022)], use of cholinesterase inhibitors [HR = 0.40; (0.27-0.59)], use of 1 to 3 other types of medication [HR = 0.57; (0.36-0.89)]. CONCLUSIONS The identification of both patient and caregiver factors predictive of attrition is of particular interest for the development and targeting of attrition prevention strategies. In patients with chronic diseases, particular attention should be paid to caregiver well-being to limit attrition.
Collapse
Affiliation(s)
- Nicola Coley
- Inserm, U558, University of Toulouse III, Toulouse, France.
| | | | | | | | | | | | | | | | | |
Collapse
|
39
|
Gardette V, Andrieu S, Gillette-Guyonnet S, Nourhashémi F, Ousset PJ, Cantet C, Lapeyre-Mestre M, Montastruc JL, Vellas B. P2‐392: Predictive factors of discontinuation and switch of cholinesterase inhibitors in Alzheimer's disease. Alzheimers Dement 2008. [DOI: 10.1016/j.jalz.2008.05.1470] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Affiliation(s)
- Virginie Gardette
- Department of Epidemiology and Public HealthUniv Toulouse III, INSERM U558ToulouseFrance
- GerontopoleToulouseFrance
| | - Sandrine Andrieu
- Department of Epidemiology and Public HealthUniv Toulouse III, INSERM U558ToulouseFrance
- GerontopoleToulouseFrance
| | - Sophie Gillette-Guyonnet
- Gerontopole, CHU ToulouseDepartment of Geriatric MedicineToulouseFrance
- Inserm, U558ToulouseFrance
| | - Fati Nourhashémi
- Gerontopole, CHU ToulouseDepartment of Geriatric MedicineINSERM U558ToulouseFrance
| | - Pierre Jean Ousset
- Gerontopole, CHU ToulouseDepartment of Geriatric MedicineINSERM U558ToulouseFrance
| | - Christelle Cantet
- Gerontopole, CHU ToulouseDepartment of Geriatric MedicineToulouseFrance
| | - Maryse Lapeyre-Mestre
- Service de Pharmacologie Clinique, EA 3696Faculté de MédecineGérontopôle, CHU de Toulouse, Université de ToulouseToulouseFrance
| | - Jean-Louis Montastruc
- Service de Pharmacologie Clinique, EA 3696Faculté de MédecineGérontopôle, CHU de Toulouse, Université de ToulouseToulouseFrance
| | - Bruno Vellas
- Gerontopole, CHU ToulouseDepartment of Geriatric MedicineINSERM U558ToulouseFrance
| |
Collapse
|
40
|
Coley N, Andrieu S, Gardette V, Gillette-Guyonnet S, Sanz C, Vellas B, Grand A. Dementia Prevention: Methodological Explanations for Inconsistent Results. Epidemiol Rev 2008; 30:35-66. [PMID: 18779228 DOI: 10.1093/epirev/mxn010] [Citation(s) in RCA: 108] [Impact Index Per Article: 6.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/31/2022] Open
|
41
|
Nourhashémi F, Ousset PJ, Gillette-Guyonnet S, Cantet C, Andrieu S, Vellas B. A 2-year follow-up of 233 very mild (CDR 0.5) Alzheimer's disease patients (REAL.FR cohort). Int J Geriatr Psychiatry 2008; 23:460-5. [PMID: 17894422 DOI: 10.1002/gps.1904] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Abstract
OBJECTIVES Making an early diagnosis of Alzheimer's Disease (AD) is becoming increasingly important. The Clinical Dementia Rating scale (CDR), a semi-structured interview with patient and caregiver, is a global rating scale designed for use in staging dementia. The primary objective of our study was to examine the evolution of AD in individuals with very mild AD (CDR 0.5) across a 2-year follow up. METHODS A cohort of AD patients (n=682) living in the community were followed during 2 years in 16 centres of the French AD network. Each subject underwent extensive medical examination including the MMSE and CDR every 6 months. RESULTS Two hundred and thirty-three AD patients were rated CDR 0.5 at baseline (mean MMSE score: 23.15+/-2.57). They were younger and reported an average duration of symptoms of approximately 0.8 years less than patients with CDR >or= 1.During the 2-year follow-up, none of the AD CDR 0.5 subjects improved; 65% of them showed an increase in the CDR score. The rate of cognitive decline was similar between the AD CDR 0.5 and CDR >or= 1 groups. The ADL decline was more significant in patients with CDR >or= 1 at inclusion. CONCLUSIONS It is certainly possible to identify AD at a very early stage focusing on intra individual change in cognitive and functional impairment. Criteria with a high sensitivity and specificity for detecting AD at an early stage will help to further develop effective pharmacological and behavioural interventions for delaying the onset and progression of the disease.
Collapse
Affiliation(s)
- Fati Nourhashémi
- CHU Toulouse, Hôpital Casselardit, Service de médecine interne et gérontologie clinique, Toulouse, France.
| | | | | | | | | | | |
Collapse
|
42
|
Benoit M, Andrieu S, Lechowski L, Gillette-Guyonnet S, Robert PH, Vellas B. Apathy and depression in Alzheimer's disease are associated with functional deficit and psychotropic prescription. Int J Geriatr Psychiatry 2008; 23:409-14. [PMID: 17918770 DOI: 10.1002/gps.1895] [Citation(s) in RCA: 51] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Abstract
BACKGROUND Apathy and depression are the most common neuropsychiatric features in Alzheimer's disease (AD). The clinical and functional specific correlates of these syndromes are not well known independently from cognitive deficits and other behavioral disturbances. MATERIAL AND METHODS Six hundred and eighty-six patients diagnosed with possible or probable AD were included in a prospective multicenter study (REAL-FR). They had an assessment of their cognitive and functional status. Neuropsychiatric symptoms were assessed with the Neuropsychiatric Inventory (NPI) and caregiver's burden was measured with Zarit's Burden Scale. RESULTS A majority of patients at any stage of the disease presented with one or several behavioral and psychological disturbances. Apathy concerned 43% of patients and, with or without depression, was associated with more pronounced deficits in global cognition, everyday life and instrumental abilities, nutritional status and with a higher burden level. A high level of psychotropic prescription, especially with antidepressant, was observed in patients with apathy. In a multivariate analysis taking into account the cognitive and functional variables of AD, apathy and depression were the only significant predictors of psychotropic prescription. CONCLUSION Some negative neuropsychiatric symptoms such as apathy and depression have a specific relation with functional and therapeutic outcomes of AD, independently from cognitive status. Further studies are needed to establish if apathy represents a particularly severe phenotype of AD.
Collapse
Affiliation(s)
- M Benoit
- Centre mémoire de Ressources et de Recherche, Hôpital Pasteur, Nice, France.
| | | | | | | | | | | | | |
Collapse
|
43
|
Nourhashemi F, Gillette-Guyonnet S, Andrieu S, Rolland Y, Ousset PJ, Vellas B. A randomized trial of the impact of a specific care plan in 1120 Alzheimer's patients (PLASA Study) over a two-year period: design and baseline data. J Nutr Health Aging 2008; 12:263-71. [PMID: 18373036 DOI: 10.1007/bf02982632] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/15/2022]
Abstract
OBJECTIVE To describe the design anf baseline patient characteristics of a multicomponent specific care and assistance plan (PLASA) study in Alzheimer's Disease (AD). The study is designed to evaluate the effect of PLASA in AD primarily looking at change in functional capacity. DESIGN Two-years prospective cluster randomized controlled trial comparing PLASA and usual care. SETTING Forty-nine hospitals in France. PARTICIPANTS 1120 community-dwelling AD. INTERVENTION Patients in the intervention group are evaluated biannually using a standardized comprehensive global assessment. In the case of decline in any one domain a standardized study protocol recommends specific physician directed intervention in addition to information and training for the caregiver. MEASUREMENTS Alzheimer Disease Cooperative Study-Activities of Daily Living scale, Resource Utilization in Dementia scale, Clinical Global Impression of Change. RESULTS At baseline, the two groups were similar regarding patient and caregiver characteristics. The mean patient age was 79.61+5.72 years and the mean MMSE 19.73+4.01 for the whole cohort. Time since dementia diagnosis was about 1.37+1.65 years in the whole cohort. Almost a third of the patients lived alone at baseline. Mean monthly time spent in caregiving in the whole cohort was 52.70+71.83 hours for instrumental activities and 17.73+51.38 hours for basic activities. CONCLUSION Persons with dementia suffer different losses at different stages of the disease and therefore accurate assessment of abilities and losses is critical to assist the person in planning for their future and for care needs. The PLASA intervention study is ongoing with 2 year follow-up to be completed in 2007.
Collapse
Affiliation(s)
- F Nourhashemi
- Hôpital Casselardit, Service de Médecine Interne et de Gérontologie Clinique, 31059 Toulouse, France.
| | | | | | | | | | | |
Collapse
|
44
|
Gillette-Guyonnet S, Andrieu S, Nourhashemi F, Reynish E, Vellas B. RESPONSE TO LETTER FROM CHENG ON CHOLINESTERASE INHIBITORS AND ALZHEIMER'S DISEASE OUTCOMES. J Gerontol A Biol Sci Med Sci 2007. [DOI: 10.1093/gerona/62.6.680-a] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
45
|
Gillette-Guyonnet S, Andrieu S, Nourhashemi F, Reynish E, Vellas B. RESPONSE TO LETTER FROM GARCIA AND COLLEAGUES ON CHOLINESTERASE INHIBITORS AND ALZHEIMER'S DISEASE OUTCOMES. J Gerontol A Biol Sci Med Sci 2007; 62:679-80. [PMID: 17595427 DOI: 10.1093/gerona/62.6.679] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
46
|
Gillette-Guyonnet S, Andrieu S, Cortes F, Nourhashemi F, Cantet C, Ousset PJ, Reynish E, Grandjean H, Vellas B. Outcome of Alzheimer's disease: potential impact of cholinesterase inhibitors. J Gerontol A Biol Sci Med Sci 2006; 61:516-20. [PMID: 16720751 DOI: 10.1093/gerona/61.5.516] [Citation(s) in RCA: 25] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
BACKGROUND Alzheimer's disease is fast becoming a major public health concern with serious economic consequences. The cholinesterase inhibitors (CEIs) offer some benefit in the symptomatic treatment of the disease. This study aims to investigate the effect of CEIs on three clinically relevant domains (rapid cognitive decline, institutionalization, and weight loss) in patients with Alzheimer's disease. METHODS A prospective observational study was performed in which a population of 455 Alzheimer's disease patients were recruited and followed up for at least 1 year between 1994 and 2002. Patients were reevaluated at 6 monthly intervals using standardized neurocognitive and geriatric evaluations in addition to complete clinical examination, standard paraclinical investigations, and recording of treatment received. RESULTS The risk of rapid cognitive deterioration was significantly decreased in patients taking CEIs for at least 1 year compared to untreated patients (odds ratio [OR]=0.56, 95% confidence interval [CI], 0.34-0.93; p=.025). The potential benefit of CEI use was also found on institutionalization (OR=0.2, 95% CI, 0.08-0.48; p<.001) and weight loss (OR=0.56, 95% CI, 0.32-0.97; p=.039) after 1 year of follow-up. CONCLUSION The special interest of this study is that all patients were recruited and followed in the same center with the same management care plan and the same medical team. This follow-up offers us a unique opportunity to compare the 1-year evolution of the disease in clinical practice before and after the marketing of CEIs and allows us to demonstrate a clinically significant improvement in patient outcome over time.
Collapse
Affiliation(s)
- Sophie Gillette-Guyonnet
- Department of Internal Medicine and Clinical Gerontology, Centre Hospitalier Universitaire La Grave-Casselardit, 170 avenue de Casselardit, TSA40031, 31059 Toulouse cedex 9, France.
| | | | | | | | | | | | | | | | | |
Collapse
|
47
|
Soto ME, Andrieu S, Gillette-Guyonnet S, Cantet C, Nourhashemi F, Vellas B. Risk factors for functional decline and institutionalisation among community-dwelling older adults with mild to severe Alzheimer's disease: one year of follow-up. Age Ageing 2006; 35:308-10. [PMID: 16533876 DOI: 10.1093/ageing/afj059] [Citation(s) in RCA: 21] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
Affiliation(s)
- Maria E Soto
- Médicine Interne et Gériatrie, CHU Purpan-Casselardit, Toulouse, Midi-Pirinées, France.
| | | | | | | | | | | |
Collapse
|
48
|
Cortes F, Gillette-Guyonnet S, Nourhashemi F, Christelle C, Vellas B. Family history of dementia does not influence the progression of Alzheimer's disease at two years: results from the REAL.FR Study. Am J Alzheimers Dis Other Demen 2006; 21:131-6. [PMID: 16634470 PMCID: PMC10833240 DOI: 10.1177/153331750602100214] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
The purpose of this study was to determine whether a family history of dementia in a first-degree relative influenced the progression of Alzheimer's disease (AD) after two years of follow-up. Patients were recruited in the REAL.FR (Réseau sur la Maladie d'Alzheimer Français) study and underwent behavioral, global, nutritional, and medical evaluation with assessment of cognitive function and independence every six months. At inclusion, 113 patients reported a family history of dementia, and 358 patients had no family history of dementia. There was no statistical difference for any factors between the two groups at baseline. After two years of follow-up, a similar percentage of patients were still followed in each group, and although most parameters showed significant deterioration, there was no difference between the two groups, indicating that a family history of dementia does not appear to influence the progression of AD.
Collapse
Affiliation(s)
- Frédéric Cortes
- Service de Médecine Interne et Gérontologie Clinique, Toulouse, France
| | | | | | | | | |
Collapse
|
49
|
Ousset P, Nourhashémi F, Balardy L, Gillette-Guyonnet S, Andrieu S, Vellas B. P2-31 Le statut nutritionnel prédit le passage à la démence dans la maladie d’alzheimer. Rev Neurol (Paris) 2005. [DOI: 10.1016/s0035-3787(05)85359-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
50
|
Gillette-Guyonnet S, Andrieu S, Nourhashemi F, de La Guéronnière V, Grandjean H, Vellas B. Cognitive impairment and composition of drinking water in women: findings of the EPIDOS Study. Am J Clin Nutr 2005; 81:897-902. [PMID: 15817869 DOI: 10.1093/ajcn/81.4.897] [Citation(s) in RCA: 40] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
BACKGROUND The concentration of aluminum or silica in drinking water may be a potential environmental risk factor for Alzheimer disease (AD). OBJECTIVES The objective was to investigate at baseline the potential association between the composition of drinking water and the level of cognitive function in women taking part in the Epidemiology of Osteoporosis (EPIDOS) Study and to determine during follow-up the effects of the composition of drinking water on the risk of AD. DESIGN Women aged >/=75 y (n = 7598) were recruited between 1992 and 1994 in 5 geographic areas of France. The participants from one center (n = 1462) were followed for </=7 y; during this time, an active search for incident cases of AD was conducted. The initial questionnaire comprised a food consumption survey with specific questions about the daily consumption of tap and mineral water. The evaluation of cognitive function was based on the Short Portable Mental Status Questionnaire. During follow-up, the diagnosis of dementia was made by a geriatrician and a neurologist. RESULTS A low silica concentration was associated with low cognitive performance at baseline. Compared with the nondemented subjects, the women with a diagnosis of AD during follow-up were older at inclusion, had a lower financial status and educational level, had a poorer perception of their own health, and had a more difficult time performing activities of daily living. A multivariate analysis including potential confounding factors showed that women with AD appeared to have been exposed to lower amounts of silica at baseline. CONCLUSIONS Silica in drinking water may reduce the risk of developing AD in elderly women. The results corroborate those of another epidemiologic study carried out in France. The potential effect of silica needs to be confirmed in additional investigations.
Collapse
|